tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

PBIGF Stock Latest News

Paradigm Biopharmaceuticals Advances Phase 3 Knee Osteoarthritis Trial
Company AnnouncementsParadigm Biopharmaceuticals Advances Phase 3 Knee Osteoarthritis Trial
20d ago
Paradigm Biopharmaceuticals’ General Meeting Results and Future Meeting Plans
PremiumCompany Announcements
Paradigm Biopharmaceuticals’ General Meeting Results and Future Meeting Plans
25d ago
Paradigm Biopharmaceuticals Secures US Ethics Approval for Phase 3 Osteoarthritis Trial
PremiumCompany Announcements
Paradigm Biopharmaceuticals Secures US Ethics Approval for Phase 3 Osteoarthritis Trial
1M ago
Paradigm Biopharmaceuticals Seeks Shareholder Approval for Strategic Resolutions
PremiumCompany Announcements
Paradigm Biopharmaceuticals Seeks Shareholder Approval for Strategic Resolutions
2M ago
Paradigm Biopharmaceuticals Advances Phase 3 Trial for Osteoarthritis Treatment
PremiumCompany Announcements
Paradigm Biopharmaceuticals Advances Phase 3 Trial for Osteoarthritis Treatment
2M ago
Paradigm Biopharmaceuticals to Present at NWR Virtual Healthcare Conference
PremiumCompany AnnouncementsParadigm Biopharmaceuticals to Present at NWR Virtual Healthcare Conference
3M ago
Paradigm Biopharmaceuticals Reports Reduced Losses Amid Ongoing Osteoarthritis Treatment Development
Premium
Company Announcements
Paradigm Biopharmaceuticals Reports Reduced Losses Amid Ongoing Osteoarthritis Treatment Development
4M ago
Paradigm Biopharmaceuticals Secures Ethics Approval for Phase 3 Osteoarthritis Trial
Premium
Company Announcements
Paradigm Biopharmaceuticals Secures Ethics Approval for Phase 3 Osteoarthritis Trial
4M ago
Paradigm Biopharmaceuticals Director Acquires New Options
PremiumCompany Announcements
Paradigm Biopharmaceuticals Director Acquires New Options
4M ago
Paradigm Biopharmaceuticals Announces Director’s Securities Interest Update
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces Director’s Securities Interest Update
4M ago
Paradigm Biopharmaceuticals Issues New Securities to Bolster Strategic Initiatives
PremiumCompany Announcements
Paradigm Biopharmaceuticals Issues New Securities to Bolster Strategic Initiatives
4M ago
Paradigm Biopharmaceuticals Amends Bonus Issue Announcement
PremiumCompany Announcements
Paradigm Biopharmaceuticals Amends Bonus Issue Announcement
5M ago
Paradigm Biopharmaceuticals Announces Strategic Bonus Issue of Securities
PremiumCompany AnnouncementsParadigm Biopharmaceuticals Announces Strategic Bonus Issue of Securities
5M ago
Paradigm Biopharmaceuticals Unveils Shareholder Reward Program with Potential $111M Fundraising
Premium
Company Announcements
Paradigm Biopharmaceuticals Unveils Shareholder Reward Program with Potential $111M Fundraising
5M ago
Paradigm Biopharmaceuticals Advances Phase 3 Trials with Strong Financial Backing
Premium
Company Announcements
Paradigm Biopharmaceuticals Advances Phase 3 Trials with Strong Financial Backing
5M ago
Paradigm Biopharmaceuticals Announces ASX Quotation of Securities
PremiumCompany Announcements
Paradigm Biopharmaceuticals Announces ASX Quotation of Securities
5M ago
Paradigm Biopharmaceuticals Strengthens Financial Position with R&D Tax Incentive
PremiumCompany Announcements
Paradigm Biopharmaceuticals Strengthens Financial Position with R&D Tax Incentive
5M ago
Paradigm Biopharmaceuticals to Release Escrowed Securities from Employee Share Plan
PremiumCompany Announcements
Paradigm Biopharmaceuticals to Release Escrowed Securities from Employee Share Plan
5M ago
Paradigm Biopharmaceuticals Updates on Director’s Securities
PremiumCompany Announcements
Paradigm Biopharmaceuticals Updates on Director’s Securities
6M ago
Paradigm Biopharmaceuticals Issues New Performance Rights
PremiumCompany AnnouncementsParadigm Biopharmaceuticals Issues New Performance Rights
6M ago
Paradigm Biopharmaceuticals Issues New Shares Amid Drug Development Focus
Premium
Company Announcements
Paradigm Biopharmaceuticals Issues New Shares Amid Drug Development Focus
6M ago
Paradigm Biopharma Highlights Investment Risks and Cautions
Premium
Company Announcements
Paradigm Biopharma Highlights Investment Risks and Cautions
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >